Page last updated: 2024-12-09
1,3-dibutyl-2-thiourea
Description
1,3-dibutyl-2-thiourea, also known as DBTU, is an organic compound that belongs to the thiourea family. It is a white, crystalline solid with a faint, sulfurous odor.
**Structure and Properties:**
* **Formula:** C9H20N2S
* **Molecular Weight:** 192.35 g/mol
* **Melting Point:** 66-68 °C
* **Boiling Point:** 240-245 °C
**Importance in Research:**
1,3-dibutyl-2-thiourea (DBTU) plays a significant role in various research areas, including:
**1. Organic Synthesis:**
* **Catalyst:** DBTU acts as a highly effective catalyst in a wide range of organic reactions, including:
* **Ring-opening metathesis polymerization (ROMP):** DBTU is used as a catalyst for the polymerization of cyclic olefins to form polymers with controlled molecular weights and structures.
* **Cyclopropanation:** DBTU catalyzes the formation of cyclopropanes from alkenes and diazoalkanes.
* **Carbon-carbon bond formation:** DBTU promotes various carbon-carbon bond-forming reactions, such as Michael additions and aldol condensations.
* **Reagent:** DBTU can also be used as a reagent for the synthesis of various organic compounds, including thioureas, isothiocyanates, and amides.
**2. Materials Science:**
* **Polymer Synthesis:** DBTU is employed in the synthesis of novel polymers with unique properties, such as high thermal stability and conductivity.
* **Nanomaterials:** DBTU can be used in the synthesis of nanoparticles, nanowires, and other nanomaterials with potential applications in electronics, catalysis, and biomedical engineering.
**3. Analytical Chemistry:**
* **Spectroscopy:** DBTU exhibits characteristic spectroscopic properties that can be utilized for analytical purposes, such as UV-Vis spectroscopy and mass spectrometry.
* **Chromatography:** DBTU can serve as a stationary phase in chromatography, allowing for the separation and identification of different compounds.
**4. Environmental Applications:**
* **Pollution Remediation:** DBTU has shown potential for the removal of heavy metals and other pollutants from wastewater and soil.
**5. Medicinal Chemistry:**
* **Drug Discovery:** DBTU is being explored as a potential lead compound for the development of new drugs, especially those targeting the nervous system and cancer.
**In summary, 1,3-dibutyl-2-thiourea (DBTU) is a versatile compound with a wide range of applications in research. Its catalytic activity, synthetic versatility, and potential for use in various scientific fields make it an important tool for chemists, materials scientists, and other researchers.**
1,3-dibutyl-2-thiourea: may cause contact dermatitis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N,N'-dibutylthiourea : Thiourea in which each nitrogen carries a butyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 2723622 |
CHEMBL ID | 3183795 |
CHEBI ID | 138415 |
SCHEMBL ID | 17219 |
SCHEMBL ID | 11844895 |
MeSH ID | M0106444 |
Synonyms (66)
Synonym |
pennzone b |
dibutylthiourea |
nsc-3735 |
n,n'-dibutylthiourea |
nsc4148 |
1,3-di-n-butyl-2-thiourea |
urea,3-di-n-butyl-2-thio- |
usaf ek-2138 |
1,3-dibutyl-2-thiourea |
nsc-4148 |
wln: suym4 & m4 |
109-46-6 |
thiourea,n'-dibutyl- |
1,3-dibutylthiourea |
nsc3735 |
urea,3-dibutyl-2-thio- |
urea, 1,3-dibutyl-2-thio- |
thiourea, n,n'-dibutyl- |
n,n'-di-n-butylthiourea |
n,n'-dibutylthiourea, 97% |
urea, 1,3-di-n-butyl-2-thio- |
urea,1,3-dibutyl-2-thio- |
brn 0507434 |
einecs 203-674-6 |
thiate u |
nsc 3735 |
ai3-08621 |
MAYBRIDGE1_007237 |
inchi=1/c9h20n2s/c1-3-5-7-10-9(12)11-8-6-4-2/h3-8h2,1-2h3,(h2,10,11,12 |
STK378358 |
dbtu |
sym-dibutylthiourea |
s-dibutylthiourea |
CHEBI:138415 |
D0301 |
AKOS003718653 |
HMS562A21 |
A802042 |
NCGC00248245-01 |
BBL002999 |
1,3-dibutyl-thiourea |
unii-3154m2q6gd |
3154m2q6gd , |
tox21_300986 |
dtxcid6022187 |
cas-109-46-6 |
NCGC00254888-01 |
dtxsid8042187 , |
bis(butylamino)methane-1-thione |
FT-0629391 |
di-n-butyl-2-thiourea, 1,3- |
AB01334003-02 |
SCHEMBL17219 |
1,3-di-n-butylthiourea |
1.3-dibutyl-thiourea |
SCHEMBL11844895 |
CHEMBL3183795 |
n,n'-di-normal-butylthiourea |
mfcd00004926 |
J-002288 |
F0001-0195 |
AS-19751 |
Q19059365 |
A934580 |
NCGC00248245-02 |
CS-0076311 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
" Daily dosage levels (mg/kg/day) were ETU at 0, 15, 25 and 35; DMT at 0, 15, 25, 50, 100, and 200; DBT at 0, 15, 25, 50, 100, and 200; and DPT at 0, 25, 50, 100, and 200." | ( Difference in the developmental toxicity of ethylenethiourea and three N,N'-substituted thiourea derivatives in rats. de Ceaurriz, J; Langonne, I; Sabate, JP; Saillenfait, AM, 1991) | 0.28 |
Roles (1)
Role | Description |
allergen | A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (16)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 68.5896 | 0.0007 | 14.5928 | 83.7951 | AID1259368 |
AR protein | Homo sapiens (human) | Potency | 51.9536 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 48.5577 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 45.9174 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 8.6349 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 24.4979 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 42.4206 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 63.7031 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 54.9410 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 34.3762 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 54.9410 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 46.2271 | 0.0237 | 23.2282 | 63.5986 | AID743241 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 51.9536 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 61.1306 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 61.1306 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 29.1414 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (36.36) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.76 (24.57) | Research Supply Index | 2.64 (2.92) | Research Growth Index | 4.40 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 8 (61.54%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (38.46%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |